Posted by Michael Wonder on 15 Jul 2023
European Medicine Agency accepts Intas' marketing authorisation application for DMB-3115, a proposed biosimilar to Stelara (ustekinumab)
14 July 2023 - Therapeutic equivalence and safety confirmed between DMB-3115 and Stelara in global Phase III trial.
Intas Pharmaceuticals announced that the EMA confirms acceptance of the marketing authorisation application for DMB-3115, a biosimilar of Stelara (ustekinumab).
